Interventional Oncology Devices | Market Insights | Japan | 2022

The Japanese interventional oncology device market saw a relatively limited impact of the COVID-19 pandemic, owing to the less elective nature of cancer procedures and progressively deteriorating disease conditions. The market will grow slowly due to limited adoption of minimally invasive interventional oncology procedures, substantiated by Japanese guidelines and increasing developments in anticancer drugs, limiting the growth.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Japan across a 12-year period.

The COVID-19 pandemic had a relatively limited impact on the Japanese interventional oncology device market in 2020.

How has the COVID-19 pandemic affected the different segments of the interventional oncology device market?

How has the recovery of impacted procedures been through 2021?

How will the trend in interventional oncology device market be in the post pandemic era?

Alternative forms of treatment are commonly used to treat cancer in Japan.

What alternatives compete with interventional oncology devices, and how well do they compliment or compete with the existing products?

Regulatory approval delays will impact the interventional oncology device market in Japan.

How has regulatory approval delays impacted the Japanese interventional oncology device market?

What new devices are anticipated to enter the Japanese market within the forecast period, and when are they expected to launch?

Gelatin sponges represent a large portion of the Japanese embolization device market.

What are the recent developments in the radioembolization device space that would impact the Japanese market?

What are the factors affecting physician adoption of interventional oncology procedures over surgical methods?

Which companies represent the major players in the embolization device market?